Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dextromethorphan/quinidine - Avanir Pharmaceuticals

Drug Profile

Dextromethorphan/quinidine - Avanir Pharmaceuticals

Alternative Names: AVP-923; Dextromethorphan HBr/quinidine sulfate; Dextromethorphan hydrobromide/quinidine sulfate; Neurodex; Nuedexta; Quinidine/dextromethorphan; Zenvia

Latest Information Update: 27 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Center for Neurologic Study
  • Developer Avanir Pharmaceuticals
  • Class Analgesics; Antitussives; Cinchona alkaloids; Morphinans; Quinuclidines; Small molecules
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; NMDA receptor antagonists; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Sigma-1 receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Emotional lability
  • No development reported Agitation; Migraine; Neuropathic pain
  • Discontinued Diabetic neuropathies; Drug-induced dyskinesia

Most Recent Events

  • 27 Nov 2018 No development reported - Phase-II for Agitation in USA (PO)
  • 27 Nov 2018 No development reported - Phase-II for Migraine in USA (PO)
  • 30 Sep 2018 Discontinued - Phase-II for Drug-induced dyskinesia in USA (PO) (Otsuka Pharmaceutical pipeline, September 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top